The latest progress and policy interpretation of medical insurance reimbursement for Talazoparib

Talazoparib (Talazoparib), as an oral PARP inhibitor, is mainly used for targeted therapy in patients with BRCA mutation-positive breast and ovarian cancer. In recent years, the drug has obtained marketing approval in China, and patients can purchase the original drug or imported overseas drug through local hospital pharmacies. Regarding the medical insurance reimbursement policy, some regions in the country are advancing the pilot work of including it in medical insurance, but the overall coverage is still limited. When actually purchasing drugs, patients need to consult the hospital pharmacy and medical insurance related policies in advance to clarify the reimbursement ratio and process.

In terms of price, the domestic selling price of talazoparib varies between hospitals and regions, and the price of overseas imported drugs is relatively high. For example, the Hong Kong and European version of the original drug 0.25mg30 tablets are priced between RMB 10,000 and RMB 20,000, while the price of the original drug 1mg 30 tablets can reach more than RMB 50,000. For patients, this price may bring greater financial pressure during long-term treatment, so the progress of medical insurance reimbursement is of great significance to reduce the burden on patients.

In addition, the Laotian generic version of talazoparib is more advantageous in terms of price. 1mg*30 tablets are priced at about 4,000 yuan. This provides another relatively economical way for domestic patients to obtain it, but since it is a generic drug, patients should confirm the quality and channel reliability of the drug before use, and conduct treatment under the guidance of a professional doctor to ensure efficacy and safety. Generic drugs may not be fully included in medical insurance in some areas, so policy changes still need to be paid attention to.

Generally speaking, the domestic medical insurance reimbursement policy for talazoparib is gradually improving, but the coverage and proportion are not yet uniform. Before purchasing drugs, patients need to fully understand local medical insurance policies, drug prices and reimbursement status, and communicate with doctors about reasonable treatment plans. In the context of constantly updating policies, paying attention to official announcements and hospital pharmacy information can help patients better plan medication costs and ensure the accessibility and continuity of treatment.

Reference:https://en.wikipedia.org/wiki/Talazoparib